Our first Chiesi Week – the annual event dedicated to country managers and executives -, has filled us with gratitude and inspiration! Over 450 participants and 15+ speakers from around the globe converged in Parma to shape the future of our company. During this transformative event, we immersed ourselves in external insights, patients’ perspectives, and internal success stories. Together, we reaffirmed our purpose and defined our path for the days ahead. Explore some of the unforgettable highlights from this remarkable week. 🚀 #ChiesiThePlaceToBe #AtChiesiWeACT
Chiesi Group
Fabbricazione di prodotti farmaceutici
Parma, Emilia-Romagna 208.820 follower
Chi siamo
Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we’re part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 31 countries, and counts more than 6,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For further information please visit www.chiesi.com
- Sito Web
-
http://www.chiesi.com
Link esterno per Chiesi Group
- Settore
- Fabbricazione di prodotti farmaceutici
- Dimensioni dell’azienda
- 5001 - 10.000 dipendenti
- Sede principale
- Parma, Emilia-Romagna
- Tipo
- Società privata non quotata
- Settori di competenza
- Pharmaceuticals, Respiratory, Neonatology, Special care e Rare Diseases
Località
-
Principale
Ottieni indicazioni
Via Paradigna, 131
Parma, Emilia-Romagna 43122, IT
-
Ottieni indicazioni
Via Palermo 26/A
Parma, 43122, IT
Dipendenti presso Chiesi Group
Aggiornamenti
-
Creating a positive and inclusive workplace is central to Chiesi's mission. Creating value for people is reflected in our dedication to fair pay, fostering a diverse workforce, and promoting work-life balance for everyone at Chiesi. We believe that investing in our employees' well-being drives our shared success. Discover more here: https://lnkd.in/dZcXShMy #ChiesiGroup #ChiesiThePlaceToBe
-
Our dedication to improving patient health through innovative therapeutic solutions is at the heart of everything we do. In 2023, we invested significantly in research and development to address the needs of patients. Learn more about our commitment to scientific progress in respiratory diseases, rare and ultra-rare diseases, and specialty care: https://www.chiesi.com/en/ #ChiesiGroup
-
-
Back from Stockholm, where our Global D&I Committee convened for the annual meeting, and it was an inspiring gathering. Together, they shaped future plans for diversity and inclusion. The focus was on three key pillars: 📖 D&I Narrative: We’re forging our collective story, celebrating our unique perspectives and experiences. 🤝 Evolution the ERGs: we are committed to expand our Chiesi Affinity Networks, fostering connections across our organization. 🌍 An initial conversation on multiculturalism and a global mindset: these powerful forces propel our commitment to a more inclusive world Embracing diversity fuels innovation and drives positive change. Together, we’re building a work environment where everyone feels welcomed and empowered for their own diversity. #ChiesiThePlaceToBe #DiversityAndInclusion #DEI
-
-
The success of Chiesi is anchored in a steadfast commitment to sustainability, shared value and high ethical standards. We believe that fostering strong communities and generating shared prosperity are integral to our value creation process. Discover more here: https://lnkd.in/dZcXShMy #ChiesiGroup
-
🌈 Chiesi celebrates #PrideMonth! This month, we redouble our efforts to cultivate an inclusive and diverse workplace, empowering the LGBTQIA+ community. At Chiesi, inclusion transcends mere rhetoric. We are committed to nurturing a culture where everyone is welcomed and valued—where uniqueness is celebrated, and love is honored in all its forms. Join us in this celebration, not just this month but every day, as we strive to create a space where everyone can thrive. Because at Chiesi, we believe that when we uplift one another, we all rise together. #ChiesiThePlaceToBe #InclusionMatters #LGBTQIA
-
Exciting News! Chiesi Group has been recognized at the M&A Awards 2024! 🏆 This prestigious award, organized by Fineurop Soditic S.p.A. Soditic and KPMG, celebrates excellence in mergers and acquisitions. The acquisition of Amryt Pharma, completed last year, represented a key milestone in our journey to advancing innovative treatments and improving lives of people with rare and ultra-rare diseases worldwide. Chiesi Global Rare Diseases #rarediseases
Per la categoria M&A ‘Italia su Estero’ sono state premiate: 🥇 Chiesi Group per l'acquisizione dell'irlandese Amryt Pharma L'operazione consente alla multinazionale biofarmaceutica di proprietà della Famiglia Chiesi, di ampliare il portafoglio prodotti con nuove soluzioni terapeutiche in ambito di malattie rare e ultra-rare e di rafforzare la presenza internazionale. 🥇 Ariston Group per l'acquisizione della tedesca Centrotec Climate Systems Con un controvalore di 1 miliardo di euro rappresenta la più grande acquisizione nella storia del Gruppo, che rafforza così il proprio portafoglio tecnologico e il posizionamento in Europa. 🥈Alfasigma per l'acquisizione di Intercept Pharmaceuticals
-
-
Our CEO, Giuseppe Accogli and our colleague Martin Marciniak received recognition at the #ATS2024 opening ceremony for Chiesi Group’s sponsorship of the ATS Research Program Benefit. Our collaboration with ATS enables us to enhance patient care and outcomes for people with #respiratory conditions. #ATS #ChiesiGroup
Our Group CEO, Giuseppe Accogli, and Martin Marciniak, Vice President of US Medical Affairs, joined American Thoracic Society President Patricia Rivera, MD, on stage during the #ATS2024 opening ceremony to receive recognition for our Sapphire level sponsorship of the 20th year of the ATS Research Program Benefit. We are proud to partner with ATS to support pathways to advance care and outcomes for patients affected by respiratory diseases. #respiratory #ATS #ChiesiGroup #LifeinChiesi #ChiesiAir
-
-
🌈 Chiesi Group Celebrates #ParmaPRide! 🌈 On May 18th, Chiesi proudly participated in the third edition of Parma PRide, an inspiring event dedicated to celebrating the inclusion and diversity of the LGBTQIA+ community. This occasion reflects our unwavering commitment to fostering an inclusive workplace where everyone can feel welcomed and accepted for their own diversity. Our ERG Arcobaleno Plaza, alongside Barilla’s VOCE, marched through the streets of Parma, standing in solidarity with the local LGBTQIA+ community. We firmly believe that diversity is the driving force behind business success, and an inclusive environment is essential for the well-being and prosperity of all! #ChiesiThePlaceToBe #DiversityandInclusion #LGBTQIACommunity #ParmaPRide2024
-
-
Every heartbeat is a testament to hope, and for families and caregivers of premature infants, it's a journey of courage and love. We're honored to announce a significant step forward in our mission to protect these precious lives collaborating closely with Oak Hill Bio. Read more on our website: https://lnkd.in/grBwSU5D #ChiesiGroup #Partnership #ClinicalStudy #neonatology #Respiratory #respiratoryhealth
Chiesi Group and Oak Hill Bio have announced that the first patient has enrolled for the resumed Phase 2b clinical study evaluating OHB-607 for the potential prevention of Bronchopulmonary Dysplasia, the most common cause of Chronic Lung Disease in premature infants. This is a significant advancement in the shared mission of our companies with a treatment that has the potential to be the first innovative respiratory therapeutic advance for extremely preterm neonates in over thirty years. Diego Ardigò, Global Research & Development Head at Chiesi Group, comments on this new clinical trial and the company’s commitment to advancing neonatology. Read more here: https://lnkd.in/grBwSU5D #Chiesi_USA #Respiratory #Neonatology #Partnership #ClinicalStudy